Berubicin is a novel, synthetic, second-generation anthracycline-based topoisomerase II inhibitor engineered to circumvent the BBB and overcome MDR. Berubicin has been administered to humans in 4 clinical trials to date.
CNS Pharmaceuticals is exploring out-licensing opportunities for TPI-287 and Berubicin to focus on acquiring new programs aligned with its strategic priorities.
TPI 287 is a small molecule belonging to the taxane diterpenoid (taxoid) family, specifically to the abeotaxane class. Originally isolated from the bark of the Yew tree, TPI 287 is a novel synthetic microtubule inhibitor tested in over 350 patients to date.
CNS Pharmaceuticals develops therapies for serious diseases in neurology and oncology, targeting unmet patient needs with novel assets supported by biological rationale and clear regulatory pathways.
CNS Pharmaceuticals is a biotechnology company focused on advancing differentiated therapies for serious diseases in neurology and oncology, addressing significant unmet medical needs.
CNS Pharmaceuticals is transforming its strategy to build a high-value pipeline in neurology and oncology, leveraging leadership experience to pursue differentiated therapeutic opportunities.
